Clinical trials: Adrenocortical Hyperfunction
Cushing's Disease
Mifepristone in Children With Refractory Cushing's Disease
Study objectives are to obtain safety, pharmacokinetic, and pharmacodynamic data on the effect of mifepristone on glucose metabolism, body weight and the growth-hormone-IGF in children with refractory Cushing's disease.
- Trial name
- NCT01925092
- Testing
- mifepristone
- Where
- United States
- Sponsor
- Corcept Therapeutics
Adrenocortical Carcinoma
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
This study will investigate the safety and efficacy of Relacorilant in combination with Pembrolizumab for Patients with Adrenocortical Carcinoma which Produces Too Much Stress Hormone (Cortisol).
- Trial name
- NCT04373265
- Testing
- Relacorilant, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Corcept Therapeutics
Primary Aldosteronism
Study of QLS1410 in the Treatment of Primary Aldosteronism.
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of QLS1410 versus placebo, on the reduction of Seated Blood Pressure (SBP) in…
- Trial name
- NCT07550465
- Testing
- QLS1410
- Volunteers
- 60 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Cushing's Syndrome
Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion
This study will evaluate whether the drug mifepristone can improve the symptoms of Cushing's syndrome in people with ectopic adrenal corticotrophin hormone (ACTH) secretion.
- Trial name
- NCT00422201
- Testing
- Mifepristone
- Where
- 15 sites in United States, France and 3 more
- Volunteers
- 18 people
- Sponsor
- HRA Pharma
Primary Aldosteronism, Hyperaldosteronism
A Study of CIN-107 in Adults With Primary Aldosteronism
This is a multicenter, open-label study in adult patients with PA to evaluate the effectiveness and safety of CIN-107 after up to 12 weeks of treatment (Part 1), and then for eligible, consenting patients follow patients in Part…
- Trial name
- NCT04605549
- Testing
- CIN-107 2 mg dosing, CIN-107 4 mg dosing, CIN-107 8 mg dosing
- Where
- 10 sites in United States
- Volunteers
- 15 people
- Sponsor
- AstraZeneca
Primary Hyperaldosteronism
Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism
The purpose of this study is to determine if LCI699, thorough reductions in aldosterone, can lower BP in patients with Primary hyperaldosteronism.
- Trial name
- NCT00732771
- Testing
- LCI699
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Novartis
Cushing Syndrome
Observational Registry on Patients With Endogenous CS to Document Safety and Effectiveness of Ketoconazole.
This is a non-interventional, prospective, multinational, multicentre, observational study, in which data collected are those derived from routine clinical practice via an European registry on CS: ERCUSYN.
- Trial name
- KetoPASS (NCT04872920)
- Where
- 6 sites in Croatia, France and 2 more
- Volunteers
- 200 people
- Sponsor
- HRA Pharma
Cushing's Syndrome
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome.
- Trial name
- NCT00936741
- Testing
- mifepristone
- Where
- 15 sites in United States
- Volunteers
- 30 people
- Sponsor
- Corcept Therapeutics
Cushings Disease
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
The main purpose of this prospective, multicenter, open-label phase II study, was to evaluate the efficacy and safety of pasireotide alone or in combination with cabergoline in patients with Cushing's disease.
- Trial name
- NCT01915303
- Testing
- Pasireotide with or without cabergoline
- Where
- 29 sites in United States, Argentina and 14 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Cushing Syndrome, Cushing Disease
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
A Phase 1b/2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an…
- Conditions
- Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome
- Trial name
- NCT05804669
- Testing
- atumelnant
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Primary Aldosteronism
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism
This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in primary aldosteronism.
- Trial name
- NCT07646535
- Testing
- SAL0140 Tablets
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Cushing's Syndrome
Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome
Chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome.
- Trial name
- RE-KLAIM (NCT02663609)
- Testing
- No intervention
- Volunteers
- 24 people
- Sponsor
- Corcept Therapeutics
Cushings Disease
Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
The study aimed to confirm long-term efficacy and safety of LCI699 for the treatment of patients with Cushing's disease. It was a pivotal trial which supported the registration of LCI699 for the treatment of patients with…
- Trial name
- NCT02180217
- Testing
- osilodrostat
- Where
- 60 sites in United States, Argentina and 17 more
- Volunteers
- 137 people
- Sponsor
- Novartis Pharmaceuticals
Primary Aldosteronism
Study of CS-3150 in Patients With Primary Aldosteronism
To examine antihypertensive effect and safety of CS-3150 in patients with primary aldosteronism.
- Trial name
- NCT02885662
- Testing
- CS-3150
- Where
- Japan
- Volunteers
- 44 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Anxiety, Stress
An Exploratory Investigation of a Supplement to Promote Cognitive Health Benefits
The Smart Supplement has 20 vitamins and minerals that have strong track records of demonstrating positive health effects, both physiologically and cognitively.
- Conditions
- Anxiety, Stress, Memory Deficits, Cortisol Overproduction
- Trial name
- NCT05523115
- Testing
- Heights Smart Supplement
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Heights
Resistant Hypertension, Hypercortisolism
Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)
This is a non-interventional study to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN) and will enroll approximately 1000 patients at approximately 45 sites in the United…
- Trial name
- MOMENTUM (NCT06829537)
- Where
- 50 sites in United States
- Volunteers
- 1,143 people
- Sponsor
- Corcept Therapeutics
Cushing's Syndrome
A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease
The study treatment period is 15 days in length and includes patients with pituitary Cushing's disease who are candidates for surgical intervention as well as and patients who have recurrent Cushing's post operatively.
- Trial name
- NCT00088608
- Testing
- SOM230 s.c.
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Cushing Syndrome
A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome
This is a Phase 2 multicenter, randomized, double-blind, placebo controlled study of ATR-101 to evaluate the efficacy and safety of orally-administered ATR-101 in adults with endogenous Cushing's syndrome.
- Trial name
- NCT03053271
- Testing
- ATR-101
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 4 people
- Sponsor
- Millendo Therapeutics US, Inc.
Primary Aldosteronism
DP13 - A Phase II Study in Patients With Primary Aldosteronism
The purpose of the present phase II study is to determine whether DP13 displays the clinical safety and efficacy profile to support further development in patients with primary aldosteronism.
- Trial name
- NCT04007406
- Testing
- dexfadrostat phosphate
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- Damian Pharma AG
Cushing Syndrome, Cushing Disease
Open-label Treatment in Cushing's Syndrome
This is a long-term, open-label extension study of levoketoconazole in participants with endogenous Cushing's Syndrome.
- Trial name
- OPTICS (NCT03621280)
- Testing
- Levoketoconazole
- Where
- 30 sites in United States, Bulgaria and 9 more
- Volunteers
- 51 people
- Sponsor
- Cortendo AB